AzTrials
AzTrials

Normal ControlsNCT02095301

Herbal Extract Study

A study testing Herbal Beverage in people with Normal Controls, run by PepsiCo Global R&D at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to assess the effects of an herbal extract on mental energy in healthy human subjects. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Normal Controls
What is being tested?
Herbal Beverage
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
110 participants
Where
1 siteUnited States
Study dates
Jan 2014to Apr 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Subject is male or female, 18-70 years of age, inclusive.
  • Subject has a body mass index (BMI) ≥17.0 and ≤32.9 kg/m2 at visit 1 (day -14 to -2).
  • Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history, and routine laboratory test results.
  • Subject is a non-smoker, defined as no tobacco use for ≥6 months prior to visit 1 (day -14 to -2).
  • Individual is willing to maintain a habitual diet and physical activity patterns throughout the study period.
  • Subject is willing to consume study product and standardized meals.
Show all 11Show fewer
  • Individual is willing to abstain from caffeinated beverages and other caffeine-containing products for 12 h prior to all test visits (visits 2, 3, and 4; days 0, 3, and 6).
  • Subject is willing to abstain from alcohol consumption and avoid non-routine vigorous physical activity for 24 h prior to all test visits (visits 2, 3, and 4; days 0, 3, and 6).
  • Subject is willing to discontinue any vitamin/mineral or dietary supplements use for 2 weeks prior to visit 2 (day 0) and throughout the study period.
  • Subject is a female who is willing to schedule the randomization visit (visit 2, day 0) during the luteal phase of her menstrual cycle, defined as days 15 to the end of the cycle, where day 1 is the first day of menses, where appropriate.
  • Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Who cannot join

  • Subject is unable to understand and/or perform required tests and questionnaires (i.e., subjects cannot complete the practice tests, or tasks).
  • Subject is color blind.
  • Subject has an abnormal laboratory test result of clinical significance, including, but not limited to creatinine ≥1.5 mg/dL and ALT or AST ≥1.5X upper limit of normal at visit 1 (day -14 to -2).
  • Subject has a known allergy or sensitivity to study products or any ingredients of the study products, standardized meals/snacks provided.
  • Subject has a gastrointestinal condition that could potentially interfere with absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).
  • Subject has diagnosed depression, schizophrenia, or dementia in the last 2 years prior to visit 1 (day -14 to -2).
Show all 21Show fewer
  • Subject has a history or presence of clinically important cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, and/or stroke), renal, hepatic, endocrine (including type 1 or type 2 diabetes mellitus), pulmonary, biliary, pancreatic, or neurologic disorders.
  • Subject has extreme dietary habits (e.g., vegan, Atkins diet, very high protein).
  • Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the blood pressure measured at visit 1, (day -14 to -2). One re-test will be allowed on a separate day prior to visit 2 (day 0) for subjects whose blood pressure exceeds either of these cut points at visit 1.
  • Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Subject has signs/symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory infection). Test visits (visits 2, 3, and 4; days 0, 3, and 6) will be re-scheduled to allow subject to be symptom-free of any type of systemic infection for at least 5 d.
  • Subject has recently used antibiotics (within 5 d of any test visit; Appendix 1). Test days (visits 2, 3, and 4; days 0, 3, and 6) will be rescheduled to allow the subject to be free of antibiotic therapy for at least 5 d.
  • Subject has a history of use of psychotropic medications within 6 months of visit 2 (day 0) and throughout study period.
  • Subject has used any other prescription medications, including over-the-counter medications within 2 weeks of visit 2 (day 0; Appendix 1) and throughout study period.
  • Subject has used any over-the-counter or prescription sleep aid products (including dietary supplements) within 2 weeks of visit 2 (day 0) and throughout study period.
  • Subject has a diagnosed sleep disorder (e.g., sleep apnea) or occupation where sleep during the overnight hours is irregular (e.g., 3rd shift or overnight workers).
  • Subject consumes excessive amounts of caffeine (>4 cups of caffeinated coffee/d or >400 mg caffeine/d from caffeine-containing products).
  • Subject is a female, who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded in the source document.
  • Subject has a recent history of (within 12 months of screening; visit 1, day -14 to -2) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
  • Subject has been exposed to any non-registered drug product within 30 d prior to screening.
  • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Anil Samsong

    Addison, Illinois, 60101

Other trials in United States

About this study

The objective of this study is to assess the effects of an herbal extract on mental energy in healthy human subjects.

Conditions
Normal Controls
Being tested
Herbal Beverage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Herbal BeverageOther

Study groups in NCT02095301
Study groupRoleWhat they receive
Control plus herbal extractExperimentalControl plus herbal extract
Receives: Other: Herbal Beverage
Caffeine-free, carbonated soft drinkPlacebo comparatorCaffeine-free, carbonated soft drink

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in the ratings from computer administered tasks within the domains of mood, short-term recognition memory, and attention from pre- to post-study product consumption and between treatment conditions of an herbal extract

    Measured: 0-2 hours

Secondary outcomes (1)
  1. Measure plasma nutrient metabolites

    Measured: 0-7 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionApr 2014
  4. Study completionApr 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02095301
Sponsor's protocol ID
PEP-1320
Status last verified
Apr 2014
First submitted
10 Mar 2014
Last updated
22 Apr 2014
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing Herbal Beverage in people with Normal Controls, run by PepsiCo Global R&D at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in the ratings from computer administered tasks within the domains of mood, short-term recognition memory, and attention from pre- to post-study product consumption and between treatment conditions of an herbal extract (time frame: 0-2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2014.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in